[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ckd-mbd---chronic-kidney-disease-mineral-and-bone-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ckd-mbd---chronic-kidney-disease-mineral-and-bone-disorder":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,53,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100617004","the-cph-mbd-cohort-dietary-substudy---comparison-of-methods-for-dietary-registrations-100617004",false,"NCT07312981","The CPH-MBD Cohort Dietary Substudy - Comparison of Methods for Dietary Registrations","The CPH-MBD Cohort - Substudy on Dietary History","Inclusion Criteria:\n\n* A glomerular filtration rate of \\\u003C30 ml ml\u002Fmin\u002F1.73m2\n* 18 years and above\n\nExclusion Criteria:\n\nNone","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","3 Days","OBSERVATIONAL","The aim of the study is to assess the association between the calcium and phosphorus balance and the stage of kidney disease measured by creatinine clearence in patients with chronic kidney disease stage 4 and 5. The balance is measured a measurement between the recorded diatery intake and the urinary excretion. Additionally a comparison between image based diatery accessment and weighted records will be measured",[25,26,27,28],"CKD","Renal Insufficiency Chronic","CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder","Pre-dialysis",[30,31,32,33,34,35,36,37,38,39],"Diet","Humans","Observational","Cohort","Phosphate\u002Furine","Calcium\u002Furine","Mineral bone disorder","Elderly","Calcium Balance","Phosphate Balance","RECRUITING","2025-12-17",{"date":43,"type":44},"2025-12-31","ACTUAL",{"date":46,"type":44},"2025-12-15",{"date":48,"type":20},"2029-05-15",{"name":50,"class":51},"University of Copenhagen","OTHER",2,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":16,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":65,"conditions":66,"keywords":70,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100603786","assessment-of-mineral-and-bone-disorders-in-kidney-transplant-recipients-100603786","NCT07141043","Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients","New Directions and Perspectives in the Assessment of Mineral and Bone Disorders in Kidney Transplant Recipients","Inclusion Criteria:\n\n1. HD group: Patients undergoing HD for at least 12 months, aged 20-70 years, after signing an informed consent.\n2. KTR group: Patients with successful KTx performed at least 12 months prior to their enrollment, aged 20-70 years old, after signing an informed consent. Subjects will be eligible for inclusion regardless of KTx immunosuppression regimen, pre-transplantation history, history of pre-transplant dialysis, or whether the kidney donation was from a living or deceased donor.\n3. GPO group: men and postmenopausal women diagnosed with primary osteopenia or osteoporosis, aged 50-70 years old, after signing an informed consent.\n\nExclusion Criteria:\n\n1. HD group: Treatment with active bone therapies (excluding calcium and vitamin D); ongoing cancer treatment or recent history of malignancy, cirrhosis, recent major fractures, patients who have received transplants other than kidney, secondary causes of osteoporosis (other than CKD or transplant-related: primary hyperparathyroidism, hyperthyroidism, congenital bone disorders, sarcoidosis, severe bone trauma, malignant tumors, inflammatory bowel disease, endogenous Cushing syndrome, anti-estrogen\u002Fanti-androgen therapy, and anorexia nervosa), pregnancy and breast-feeding.\n2. KTR group: The same as for HD + return to dialysis + acute graft rejection.\n3. GPO group: The same as for HD + diabetes mellitus + prolonged glucocorticoid therapy (\\>7.5 mg Prednisone or equivalent for at least 3 months).",true,"20 Years","70 Years",{"count":64,"type":20},180,"This study aims to integrate bone measurements (including bone turnover markers (BTM), bone mineral density (BMD) measurement, vertebral fracture assessment (VFA), trabecular bone score (TBS) ) commonly used in the general population for primary osteoporosis evaluation to enhance the assessment of CKD-MBD.",[67,68,69,27],"Hemodyalysis","Kidney Tansplant","Osteoporosis",[71,69,72],"CKD-MBD","bone turnover markers","2025-08-18",{"date":75,"type":44},"2025-08-26",{"date":77,"type":44},"2025-03-19",{"date":79,"type":20},"2027-06",{"name":81,"class":51},"Grigore T. Popa University of Medicine and Pharmacy",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":82},"100585784","phase-2-activated-charcoal-use-in-chronic-kidney-disease-patients-100585784","NCT06906874","Activated Charcoal Use in Chronic Kidney Disease Patients","Efficacy and Safety of Activated Charcoal on Mineral Bone Disorder in Chronic Kidney Disease Patients","Inclusion Criteria:\n\n1. Adult aged ≥18 years with ESRD.\n2. Patients who had been on stable maintenance hemodialysis (3 times weekly) for at least 6 months.\n3. Patients receiving phosphate binders according to standard protocols established by kidney disease: Improving Global Outcomes (KDIGO).\n\nExclusion Criteria:\n\n1. Severely malnourished (as diagnosed by the department's dietitian).\n2. Treated with overnight dialysis.\n3. Primary hyperparathyroidism or persistent serum levels of intact parathyroid hormone greater than 800 pg\u002FmL.",{"count":91,"type":20},40,"INTERVENTIONAL",[94],"PHASE2","Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification. Considering that activated charcoal is generally well-tolerated and may have a favorable side effect profile compared to conventional phosphate binders, it presents a promising alternative. Until now, no clinical trial has primarily investigated the effect of activated charcoal on hyperphosphatemia in dialysis patients.",[97,98,27],"End Stage Renal Disease (ESRD)","CKD 5D, Hemodialysis","2025-08-05",{"date":101,"type":44},"2025-08-08",{"date":103,"type":20},"2025-08",{"date":105,"type":20},"2025-11",{"name":107,"class":51},"Mansoura University"]